Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Two brain zaps may lift the fog of Schizophrenia's negative symptoms

NCT ID NCT07680959

Symptom relief Sponsor: Tri-Service General Hospital (TSGH) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 02, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This trial investigates whether combining two types of brain stimulation—intermittent theta burst stimulation (iTBS) and high-definition transcranial direct current stimulation (HD-tDCS)—can reduce negative symptoms of schizophrenia, such as lack of motivation, social withdrawal, and reduced emotional expression. The study enrolls 100 adults with schizophrenia or schizoaffective disorder who have stable but prominent negative symptoms. Participants receive active or sham stimulation over three weeks, and researchers track symptom changes using standard rating scales immediately after treatment and at one and three months later.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
brain stimulation (iTBS and HD-tDCS)
What this could lead to
If it works, this could offer a new way to reduce negative symptoms of schizophrenia, improving daily functioning and quality of life.
What could go wrong
This is an early-stage trial with 100 participants, so results may not apply to everyone. Brain stimulation can cause mild side effects like headache or scalp discomfort.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects diagnosed with DSM-5 schizophrenia or schizoaffective disorder; * With a clinical presentation characterized by predominant negative symptoms, as determined by psychiatric assessment and a score of at least 20 on the Negative Symptoms Subscale of the Positive and Negative Syndrome Scale (PANSS); * Stable positive and negative symptoms for at least 4 weeks, as documented in medical records and confirmed by clinical judgment and psychiatric interview; Exclusion Criteria: * Unstable medical conditions; * Current psychiatric comorbidity or active substance use disorder (except for tobacco use disorders); * Contraindications for MRI, tDCS or rTMS; * Pregnancy or breastfeeding at the time of enrollment; * History of meningitis, encephalitis, seizures, intracranial neoplasms or surgery, severe head injury or cerebrovascular disease, or a family history of seizures; * rTMS or tDCS treatment within the past 6 months as well as a history of electroconvulsive therapy (ECT); * Any skin lesion at the stimulation sites; * Patients receiving medications that significantly change the seizure threshold; * A history of suicidal behavior within the past 6 months, or symptom worsening and emergence of suicidal ideation during the screening period.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain stimulation intervention are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

schizoaffective disorder schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain stimulation intervention Negative symptoms in schizophrenia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Tri-service general hospital

    Taipei, 114, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.